CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

encorafenib

Last Updated: December 22, 2020
Result type: Reports
Project Number: PC0233-000
Product Line: Reimbursement Review

Generic Name: encorafenib

Brand Name: Braftovi

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Metastatic colorectal cancer

Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.

Manufacturer Requested Reimbursement Criteria1: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.

Submission Type: Initial

Tumour Type: Gastrointestinal

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: Yes

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 17, 2020
Call for patient/clinician input closedJanuary 15, 2021
Clarification:

- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network

Submission receivedDecember 16, 2020
Submission acceptedJanuary 07, 2021
Review initiatedJanuary 08, 2021
Draft CADTH review report(s) provided to sponsor for commentMarch 24, 2021
Deadline for sponsors commentsApril 05, 2021
CADTH responses on draft review report(s) provided to sponsorMay 03, 2021
Expert committee meeting (initial)May 13, 2021
Draft recommendation issued to sponsorMay 26, 2021
To
May 28, 2021
Draft recommendation posted for stakeholder feedback-